Oncology Episode Payment Model in Hawaii

Sponsor

University of Pennsylvania (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT03523546

Collaborator

Hawaii Medical Service Association (Other)

Enrollment

Location

Arms

Anticipated Duration (Months)

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The HMSA Cancer Episode Payment Model (CEM) is a payment model designed to test the effects of better care coordination on health outcomes and costs of care for Hawaii Medical Services Association (HMSA) members with cancer who receive chemotherapy.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer Colon Cancer Lung Cancer	Other: Cancer Episode Payment Model (CEM)	N/A

Detailed Description

The CEM is designed to improve community health, to improve care coordination, quality, and appropriateness of care, to improve patient experience, and to implement a value-based incentive structure that appropriately rewards oncologists for cost-savings and sustained of improved quality of care.

Study Design

Study Type:

Interventional

Actual Enrollment :

7 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Health Services Research

Official Title:

Oncology Episode Payment Model in Hawaii

Actual Study Start Date :

Aug 1, 2018

Anticipated Primary Completion Date :

Jan 1, 2024

Anticipated Study Completion Date :

Jan 31, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cancer Episode Payment Model Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.	Other: Cancer Episode Payment Model (CEM) Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.
No Intervention: Fee for Service Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.

Arm

Intervention/Treatment

Experimental: Cancer Episode Payment Model

Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.

Other: Cancer Episode Payment Model (CEM)

Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.

No Intervention: Fee for Service

Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.

Outcome Measures

Primary Outcome Measures

Composite quality score [1 year]
Quality metrics included in the oncology model will be compared across the two arms.
Episode cost [6 months]
Total spending of oncology patients in the episode will be compared across the two arms.
Utilization of acute and specialty care [6 months]
Total utilization of acute and specialty care of oncology patients in the episode will be compared across the two arms

Secondary Outcome Measures

Quality of care at end of life [6 months]
Quality measures evaluating use of acute care and palliative care services at the end of life will be compared across the two arms
Survival [one year]
All cause mortality will be compared across the two arms

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Any oncologist who practices with Hawaii Oncology and is a participating provider.

Exclusion Criteria:

Any provider who does not practice with Hawaii Oncology.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hawaii Oncology	Honolulu	Hawaii	United States	96701

Sponsors and Collaborators

University of Pennsylvania
Hawaii Medical Service Association

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Amol Navathe, Principal Investigator, University of Pennsylvania

ClinicalTrials.gov Identifier:

NCT03523546

Other Study ID Numbers:

823981A

First Posted:

May 14, 2018

Last Update Posted:

Feb 8, 2022

Last Verified:

Feb 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Colonic Neoplasms

Study Results

No Results Posted as of Feb 8, 2022